Can I Swap From Mounjaro to Wegovy?
Meta Description: Can you switch from Mounjaro to Wegovy safely? Learn about washout periods, dose adjustments, side effects, and what you need to know about switching between GLP-1 weight loss medications.
Is It Safe to Switch?
Yes, switching from Mounjaro to Wegovy is safe when managed under medical supervision. Both medications are GLP-1 receptor agonists that work similarly to regulate appetite and support weight loss. Because they share this common mechanism, your body can typically tolerate the transition smoothly.
The Washout Period
One of the most important considerations is timing. You must wait at least 7 days between your final Mounjaro injection and your first Wegovy dose. Some manufacturers recommend 30 days to minimize side effects, but medical professionals often use the 7-day protocol to avoid stalling weight loss progress.
The reason for this gap is that Mounjaro remains in your system briefly, and overlapping doses could amplify side effects like nausea and gastrointestinal discomfort.
What to Expect During the Transition
Most people transition smoothly with minimal side effects. However, you may experience:
- Mild nausea or stomach upset lasting 1-2 weeks as your body adjusts
- Temporary changes in blood sugar levels and appetite
- Varying weight loss pace during the adjustment period
If you tolerated Mounjaro well, you'll likely do fine on Wegovy. Your prescriber will typically start you on a low Wegovy dose and increase gradually to minimize disruption.
Why Patients Consider Switching
Reasons for switching include:
- Cost concerns: Wegovy may be cheaper than Mounjaro for some patients
- Side effect management: Some people tolerate one medication better than the other
- Efficacy preferences: While Mounjaro produces slightly more weight loss (21% vs. 15% in trials), individual responses vary
- Supply availability: During shortages, switching becomes necessary
Important Differences to Know
Efficacy gap: Clinical trials show Mounjaro achieves approximately 21% average weight loss compared to Wegovy's 15-17% over equivalent periods. If you switch from Mounjaro to Wegovy, you may experience slightly less dramatic weight loss, though this varies individually.
Mechanism difference: Mounjaro targets both GLP-1 and GIP receptors (dual action), while Wegovy only targets GLP-1. This means your appetite suppression may feel different initially.
Dose adjustments: Wegovy starts at 0.25 mg weekly, while Mounjaro started at 2.5 mg. Your prescriber will establish an appropriate Wegovy starting dose based on your current Mounjaro level.
The Switching Process
- Complete a medical assessment with your healthcare provider confirming suitability
- Take your final Mounjaro dose
- Wait 7+ days for medication washout
- Begin Wegovy at a low starting dose
- Gradually titrate upward over 4-week intervals
- Monitor weight, blood sugar, and side effects regularly
Bottom Line
Switching between Mounjaro and Wegovy is clinically sound and commonly done. The 7-day washout period, gradual dose escalation, and medical oversight ensure safety. Most patients experience smooth transitions with manageable side effects. However, expect slightly less weight loss with Wegovy and allow your body 2-3 weeks to fully adjust.
Always consult your healthcare provider before switching - they'll ensure the transition suits your individual health profile and goals.
Check sources
- https://www.chemist-4-u.com/guides/weight-loss/switching-from-mounjaro-to-wegovy/
- https://www.medexpress.co.uk/wl-guide/switching
- https://onlinedoctor.lloydspharmacy.com/uk/lifestyle-advice/switching-from-mounjaro-to-wegovy
- https://agiletelehealth.com/blog/how-to-switch-from-semaglutide-to-trizepatide/
- https://healthsuppliesplus.com/wegovy-vs-mounjaro-clinical-guide/
- https://click2pharmacy.co.uk/mounjaro-statistics-2025/
- https://joinmochi.com/blogs/switching-from-semaglutide-to-tirzepatide
- https://zappyhealth.com/all-articles/can-i-switch-from-tirzepatide-to-semaglutide/
- https://www.iqvia.com/-/media/iqvia/pdfs/library/articles/2025/bcs2025-2680-08aug-pharmalive-launch-pr-article-2-berry-v5.pdf
